The Prevalence of Family-unit Helicobacter Pylori Infection in Jiangsu

Nanjing First Hospital, Nanjing Medical University4,000 enrolled

Overview

To assess Family-unit Helicobacter Pylori Infection rates and antimicrobial resistance rates in Jiangsu,China

The study is a sample survey of the community population in cities of Jiangsu where the centers are located.The Helicobacter pylori infection and drug-resistant gene mutations are detected by real-time PCR performed on the stools of subjects.

Study Type

OBSERVATIONAL

Enrollment

4,000

Conditions

Helicobacter Pylori Infection

Interventions

PCR test in the stoolDIAGNOSTIC_TEST

Patients will receive a prescription for a stool self-collection kit . Only the result of the PCR test in the stool will be considered for this arm. A positive test will determine Hp infection and the indication for treatment.

Eligibility

Sex: ALLMin age: 6 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. community population 2. Fecal samples can be obtained, and the sample volume meets the requirements of the collection tube instructions 3. Only one person per family can be selected 4. Voluntarily participated in this study and signed an informed consent form Exclusion Criteria: 1. The collector does not cooperate or has poor compliance; 2. Adequate and qualified fecal samples could not be obtained; 3. Stool samples were collected during diarrhea or constipation; 4. Antibiotics, bismuth preparations, proton pump inhibitors and other Hp sensitive drugs have been used within one month.

Locations (16)

Changzhou Traditional Chinese medical hospital,Affiliated to Nanjing University of Chinese Medicine

Changzhou, Jiangsu, China

NOT_YET_RECRUITING

Outcomes

Primary Outcomes

The Prevalence of Family-unit Helicobacter Pylori Infection in Jiangsu

the Helicobacter Pylori Infection rate in Jiangsu family

Time frame: 2022.12.1-2023.6.30

Secondary Outcomes

Trends of Antimicrobial Resistance of Helicobacter Pylori in Jiangsu

resistance to antimicrobial agents applicable for H. pylori eradication

Time frame: 2022.12.1-2023.6.30

Central Contacts

Zhenyu Zhang

CONTACT

+86 025-87726248 zzy6565@sina.com

Yunfan Dong

CONTACT

+86 18795993220 dyf967878@163.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.